

# Garrett M Dancik

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3061797/publications.pdf>

Version: 2024-02-01

33  
papers

1,190  
citations

430874

18  
h-index

434195

31  
g-index

34  
all docs

34  
docs citations

34  
times ranked

2633  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lower RNA expression of ALDH1A1 distinguishes the favorable risk group in acute myeloid leukemia. <i>Molecular Biology Reports</i> , 2022, 49, 3321-3331.	2.3	7
2	Aldehyde Dehydrogenase Enzyme Functions in Acute Leukemia Stem Cells. <i>Frontiers in Bioscience - Scholar</i> , 2022, 14, 8.	2.1	5
3	Using Cell Lines To Guide Neoadjuvant Therapy in Bladder Cancer: COXEN and SWOG S1314. <i>European Urology Focus</i> , 2022, , .	3.1	2
4	Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy. <i>Communications Biology</i> , 2020, 3, 720.	4.4	82
5	Elucidating the role of Agl in bladder carcinogenesis by generation and characterization of genetically engineered mice. <i>Carcinogenesis</i> , 2019, 40, 194-201.	2.8	2
6	The Cell Cycle Progression Score: Unclear Role in Renal Cell Carcinoma. <i>European Urology</i> , 2018, 74, 128-129.	1.9	6
7	Functional Impact of Chromatin Remodeling Gene Mutations and Predictive Signature for Therapeutic Response in Bladder Cancer. <i>Molecular Cancer Research</i> , 2018, 16, 69-77.	3.4	33
8	Genomic case report of a low grade bladder tumor metastasis to lung. <i>BMC Urology</i> , 2018, 18, 74.	1.4	3
9	Personalized Medicine. , 2018, , 659-673.		0
10	Genomic Heterogeneity and the Small Renal Mass. <i>Clinical Cancer Research</i> , 2018, 24, 4137-4144.	7.0	11
11	Glycogen debranching enzyme (AGL) is a novel regulator of non-small cell lung cancer growth. <i>Oncotarget</i> , 2018, 9, 16718-16730.	1.8	10
12	Nuclear CD24 Drives Tumor Growth and Is Predictive of Poor Patient Prognosis. <i>Cancer Research</i> , 2017, 77, 4858-4867.	0.9	19
13	<i>shinyGEO</i> : a web-based application for analyzing gene expression omnibus datasets. <i>Bioinformatics</i> , 2016, 32, 3679-3681.	4.1	64
14	An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis Suppression. <i>Cancer Cell</i> , 2016, 30, 432-443.	16.8	58
15	GON4L Drives Cancer Growth through a YY1-Androgen Receptor-CD24 Axis. <i>Cancer Research</i> , 2016, 76, 5175-5185.	0.9	36
16	The Prognostic Value of Cell Cycle Gene Expression Signatures in Muscle Invasive, High-Grade Bladder Cancer. <i>Bladder Cancer</i> , 2015, 1, 45-63.	0.4	7
17	<i>TERT</i> promoter mutations and telomerase reactivation in urothelial cancer. <i>Science</i> , 2015, 347, 1006-1010.	12.6	255
18	RhoC Is an Unexpected Target of RhoGDI2 in Prevention of Lung Colonization of Bladder Cancer. <i>Molecular Cancer Research</i> , 2015, 13, 483-492.	3.4	18

#	ARTICLE	IF	CITATIONS
19	Patient Mutation Directed shRNA Screen Uncovers Novel Bladder Tumor Growth Suppressors. <i>Molecular Cancer Research</i> , 2015, 13, 1306-1315.	3.4	24
20	An online tool for evaluating diagnostic and prognostic gene expression biomarkers in bladder cancer. <i>BMC Urology</i> , 2015, 15, 59.	1.4	14
21	Role in Tumor Growth of a Glycogen Debranching Enzyme Lost in Glycogen Storage Disease. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	38
22	A Cell of Origin Gene Signature Indicates Human Bladder Cancer Has Distinct Cellular Progenitors. <i>Stem Cells</i> , 2014, 32, 974-982.	3.2	40
23	Concurrent Alterations in <i>TERT</i> , <i>KDM6A</i> , and the BRCA Pathway in Bladder Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 4935-4948.	7.0	101
24	Pharmacogenomics in bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 16-22.	1.6	15
25	Robust Prognostic Gene Expression Signatures in Bladder Cancer and Lung Adenocarcinoma Depend on Cell Cycle Related Genes. <i>PLoS ONE</i> , 2014, 9, e85249.	2.5	26
26	Transcriptional Signatures of Ral GTPase Are Associated with Aggressive Clinicopathologic Characteristics in Human Cancer. <i>Cancer Research</i> , 2012, 72, 3480-3491.	0.9	36
27	A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. <i>Lancet Oncology</i> , The, 2011, 12, 137-143.	10.7	138
28	Biomarkers for prognosis and treatment selection in advanced bladder cancer patients. <i>Current Opinion in Urology</i> , 2011, 21, 420-427.	1.8	41
29	A Framework to Select Clinically Relevant Cancer Cell Lines for Investigation by Establishing Their Molecular Similarity with Primary Human Cancers. <i>Cancer Research</i> , 2011, 71, 7398-7409.	0.9	22
30	A 20 gene model for predicting nodal involvement in bladder cancer patients with muscle invasive tumors. <i>PLOS Currents</i> , 2011, 3, RRN1248.	1.4	11
31	Parameter estimation and sensitivity analysis in an agent-based model of <i>Leishmania major</i> infection. <i>Journal of Theoretical Biology</i> , 2010, 262, 398-412.	1.7	36
32	<i>mlegp</i> : statistical analysis for computer models of biological systems using R. <i>Bioinformatics</i> , 2008, 24, 1966-1967.	4.1	29
33	Cancer Publication Portal: an online tool for summarizing and searching human cancer-genomic publications. <i>F1000Research</i> , 0, 8, 2073.	1.6	1